Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Invo Fertility Q3 2026 Results: Net Loss of $2.15M, Loss Narrows

INVO Fertility, Inc. reported total revenue of $6.41 million for the nine months ended September 30, 2026, a 22% increase over the prior year, primarily driven by clinic revenue growth. Despite the revenue increase, the company realized a net loss from continuing operations of $6.71 million, impacted by significant non-cash items including a $4.35 million loss on the change in fair value of derivatives.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.21.8
Profit before tax-2.1-3.4
Net income-2.1-3.4
EPS (diluted, $ a share)$-2.44$-157.43

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+26.5%
Operating margin-66.5%
Source

10-Q filed with the SEC, NASDAQ: IVF. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Invo Fertility, Inc.: key numbers

Share price
$2.18Close, Nov 17
Market cap
$2.6M
Shares outstanding
1.19MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Invo Fertility, Inc.

All →
10:32 AM ET 8-K
Financial Results

Invo Fertility Financial Results

INVO Fertility reported Q3 2026 financial results featuring a 26% increase in total revenue to $2.2 million and a 28% growth in clinic-specific revenue. The company narrowed its net loss to $2.1 million and achieved its seventh consecutive quarter of positive clinic-level Adjusted EBITDA while significantly reducing liabilities by $5.5 million compared to year-end 2025.

Term
Q3 2026
5:11 PM ET 8-K
Reverse Stock Split

Invo Fertility Reverse Stock Split

INVO Fertility, Inc. implemented a 1-for-4 reverse stock split of its issued, outstanding, and authorized common stock effective October 30, 2026. The split reduced the number of outstanding shares to approximately 1.2 million and adjusted the authorized share count to 62.5 million to maintain compliance with Nasdaq listing requirements. Trading commenced on a split-adjusted basis under the existing symbol 'IVF' with a new CUSIP number.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.